Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2021 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR

Statistically significant reduction in hyperphagia and all other PWS behavioral parameters in Study C602 Statistically significant improvements compared to natural history of PWS from the PATH...
July 28, 2021 16:05 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results

REDWOOD CITY, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
July 06, 2021 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

REDWOOD CITY, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
June 02, 2021 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a

REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
May 21, 2021 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021

REDWOOD CITY, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
May 20, 2021 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit

REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
May 05, 2021 16:01 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

REDWOOD CITY, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
May 04, 2021 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Results Show Improvement in Multiple Behavioral Domains Following Treatment with DCCR Data Presented in a Poster at the Pediatric Academic Societies Annual Meeting REDWOOD CITY, Calif., May 04,...
April 14, 2021 20:40 ET | Source: Soleno Therapeutics

Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall

REDWOOD CITY, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
March 09, 2021 16:01 ET | Source: Soleno Therapeutics

Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference

REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...